"The medication being recalled is telmisartan and amlodipine in 40-milligram and 5-milligram doses, respectively. Both medications were distributed in 30-count bottles from Mylan Pharmaceuticals Inc. by prescription only.
These medications are being recalled due to a “superpotent drug” issue. The telmisartan content in the medications exceeds the specifications, meaning the overall composition of the medicine is off and it’s too potent."
Of course, if you are importing these meds from India you have no idea about any potential issues. That said, if you are already on 80mg telmisartan, you are on the max dose, going to 160mg will have essentially no further impact on BP.
The recalled product is itself made in India — the FDA notice lists it as “Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA, Made in India , NDC 0378-1075-93.” So the issue isn’t a general “Indian manufacturing” problem; it’s a lot-specific blend uniformity problem at a particular contract manufacturing site.
There’s little reason to expect the same issue in other Indian-manufactured telmisartan brands, for several reasons:
It’s lot-specific. Only five lots (3228113–3228121) are affected, all from the same production run. This points to a localized process deviation (e.g., mixing or content uniformity during a particular batch), not a systemic API or formulation problem.
It was caught internally. Viatris (the successor to Mylan) voluntarily initiated the recall on Oct. 1, meaning their own quality-control testing flagged the superpotency before patients reported problems.
Class III classification. The FDA deemed it unlikely to cause adverse health consequences, suggesting the excess telmisartan was modest.
Different manufacturers, different processes. Brands like Telma (Glenmark), Cresar (Cipla), Tide (Dr. Reddy’s), and others use their own facilities, equipment, and QC protocols. A deviation at one contract site doesn’t transfer to another.
Telmikind is not affected either. It is made by Mankind Pharma Ltd — a completely separate company from Viatris/Mylan. The recall is limited to one specific product: Viatris’s telmisartan 40 mg / amlodipine 5 mg combination tablets (NDC 0378-1075-93), five specific lots, from one particular contract manufacturing site in India.
Telmikind is a standalone telmisartan tablet (no amlodipine), produced at Mankind’s own facilities under its own QC. There’s no shared manufacturing line, no shared NDC, and no lot overlap. The same reasoning applies to all the other Indian brands — Telma, Telsartan, Telsar, etc. Each is an independent product with its own facility and quality system.
The only thing that would make Telmikind a concern is if it were somehow sourced from the same contract manufacturer and the same production run as the recalled Viatris lots — and there’s no indication of that.
That said, if you want to be cautious, you can check the lot/expiration date on any telmisartan product against the FDA’s recall notice (available on fda.gov) to confirm it’s not one of the five affected lots.